Compass Pathways PLC Sponsored ADR $CMPS Stock: CenterBook Partners LP Grows Stake

CenterBook Partners LP grew its stake in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 454.1% in the third quarter, Holdings Channel reports. The firm owned 695,943 shares of the company’s stock after acquiring an additional 570,349 shares during the period. CenterBook Partners LP’s holdings in Compass Pathways were worth $8,658,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Eagle Health Investments LP boosted its position in Compass Pathways by 35.6% in the 1st quarter. Eagle Health Investments LP now owns 2,060,427 shares of the company’s stock valued at $11,394,000 after buying an additional 541,039 shares during the period. Orbimed Advisors LLC bought a new stake in shares of Compass Pathways during the first quarter valued at approximately $6,363,000. Affinity Asset Advisors LLC raised its stake in shares of Compass Pathways by 454.2% during the first quarter. Affinity Asset Advisors LLC now owns 1,108,483 shares of the company’s stock valued at $6,130,000 after acquiring an additional 908,483 shares in the last quarter. Eversept Partners LP purchased a new stake in shares of Compass Pathways in the first quarter valued at approximately $3,749,000. Finally, Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Compass Pathways by 23.6% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 399,506 shares of the company’s stock valued at $4,970,000 after purchasing an additional 76,297 shares during the period. 46.19% of the stock is currently owned by institutional investors.

Compass Pathways Stock Up 10.2%

Compass Pathways stock traded up $0.80 during mid-day trading on Friday, reaching $8.61. 3,757,104 shares of the company were exchanged, compared to its average volume of 3,011,761. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 1.30. The firm has a market cap of $1.19 billion, a P/E ratio of -2.47 and a beta of 2.43. The business has a fifty day moving average of $12.32 and a 200 day moving average of $10.41. Compass Pathways PLC Sponsored ADR has a 12-month low of $4.88 and a 12-month high of $15.87.

Compass Pathways (NASDAQ:CMPS) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.08. Research analysts anticipate that Compass Pathways PLC Sponsored ADR will post -0.83 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CMPS has been the topic of several research reports. B. Riley Financial raised their price objective on Compass Pathways from $17.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Wells Fargo & Company dropped their price target on Compass Pathways from $13.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Wednesday. BTIG Research reissued a “buy” rating and set a $25.00 price target on shares of Compass Pathways in a research report on Tuesday. HC Wainwright cut their price target on Compass Pathways from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Finally, Wall Street Zen downgraded Compass Pathways from a “sell” rating to a “strong sell” rating in a report on Saturday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $23.14.

Compass Pathways Profile

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.